EndeavorRx
Earlier this year, the prescription digital therapeutics company said it would put programs related to cognitive health outside of ADHD on hold.
Also: Fitbit may be able to tell you how much you snore, and psychedelic-focused startup Mind Cure Health joins the DTx Alliance.
The Akili team took the latest trends in video game development paired with user-feedback to create the updates.
The digital therapeutic is designed to treat children ages 8 to 12 with ADHD, but the two studies announced this week will focus on an adult population.
The digital therapeutic for children's ADHD symptoms received a De Novo clearance last summer.
The long-awaited decision is the first regulatory authorization for Akili, and the first game-based therapeutic that the FDA has greenlit for any condition.